Columbia University spinout Foli Bio is developing stool‑based RNA‑seq panels that use exfoliated fecal RNA to predict drug response and monitor inflammatory bowel disease (IBD), with the stated aim of reducing the need for invasive endoscopies. The company’s approach sequences human and microbial RNA shed into stool to extract disease‑relevant signatures tied to treatment outcomes. If validated, fecal RNA diagnostics could provide a noninvasive tool for real‑time therapy selection and monitoring in IBD clinical care and drug development. Foli Bio plans to position the panels both as clinical decision tools and as endpoints for trials where serial endoscopy is currently required.